LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Search

Ligand Pharmaceuticals Inc

Închisă

SectorSănătate

181.99 -0.62

Rezumat

Modificarea prețului

24h

Curent

Minim

179.25

Maxim

185.95

Indicatori cheie

By Trading Economics

Venit

112M

117M

Vânzări

115M

P/E

Medie Sector

81.352

77.671

Marjă de profit

101.569

Angajați

68

EBITDA

87M

149M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+31.03% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

-485M

3.6B

Deschiderea anterioară

182.61

Închiderea anterioară

181.99

Sentimentul știrilor

By Acuity

56%

44%

329 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Ligand Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

10 dec. 2025, 22:02 UTC

Câștiguri

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10 dec. 2025, 21:46 UTC

Câștiguri

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10 dec. 2025, 23:52 UTC

Achiziții, Fuziuni, Preluări

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10 dec. 2025, 23:43 UTC

Market Talk

Nikkei May Rise After Fed Rate Cut -- Market Talk

10 dec. 2025, 23:36 UTC

Market Talk

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10 dec. 2025, 23:20 UTC

Câștiguri

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10 dec. 2025, 23:15 UTC

Câștiguri

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10 dec. 2025, 22:59 UTC

Market Talk
Câștiguri
Achiziții, Fuziuni, Preluări

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10 dec. 2025, 22:45 UTC

Market Talk

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10 dec. 2025, 22:40 UTC

Câștiguri

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 dec. 2025, 22:06 UTC

Achiziții, Fuziuni, Preluări

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 dec. 2025, 22:06 UTC

Câștiguri

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 dec. 2025, 22:02 UTC

Câștiguri

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 dec. 2025, 22:00 UTC

Câștiguri

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10 dec. 2025, 21:53 UTC

Câștiguri

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 dec. 2025, 21:50 UTC

Achiziții, Fuziuni, Preluări

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10 dec. 2025, 21:50 UTC

Market Talk
Câștiguri
Achiziții, Fuziuni, Preluări

Financial Services Roundup: Market Talk

10 dec. 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

10 dec. 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

10 dec. 2025, 21:45 UTC

Achiziții, Fuziuni, Preluări

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 dec. 2025, 21:33 UTC

Câștiguri

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10 dec. 2025, 21:32 UTC

Câștiguri

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 dec. 2025, 21:28 UTC

Achiziții, Fuziuni, Preluări

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10 dec. 2025, 21:25 UTC

Câștiguri

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 dec. 2025, 21:18 UTC

Achiziții, Fuziuni, Preluări

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10 dec. 2025, 21:16 UTC

Câștiguri

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10 dec. 2025, 21:15 UTC

Achiziții, Fuziuni, Preluări

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10 dec. 2025, 21:15 UTC

Câștiguri

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10 dec. 2025, 21:14 UTC

Câștiguri

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10 dec. 2025, 21:14 UTC

Câștiguri

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Comparație

Modificare preț

Ligand Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

31.03% sus

Prognoză pe 12 luni

Medie 243.5 USD  31.03%

Maxim 275 USD

Minim 220 USD

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruLigand Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

7 ratings

7

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

102.5 / 109.24Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Very Strong Bearish Evidence

Termen lung

Weak Bullish Evidence

Sentiment

By Acuity

329 / 374 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
help-icon Live chat